Showing results (121-130 of 3,316) with videos related to
Sort By:
Pageof 332
Journal of Clinical Psychopharmacology|April 26, 2020
Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant SchizophreniaHerbert Y Meltzer, Daniel B Share, Karu Jayathilake, et al.Journal of Clinical Psychopharmacology|April 26, 2020
Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive DisorderMarlene P Freeman, Rebecca S Hock, George I Papakostas, et al.Journal of Clinical Psychopharmacology|April 26, 2020
Pregabalin as a Treatment for Anxiety in Patients With Dementia With Lewy Bodies: A Case SeriesKurt Segers, Ermioni Baxevani, Florence Benoit, et al.Journal of Clinical Psychopharmacology|April 26, 2020
Prolonged Ketamine and Norketamine Excretion Profiles in Urine After Chronic Use: A Case SeriesLutea A A de Jong, Rouhollah Qurishi, Marieke P J Stams, et al.Journal of Clinical Psychopharmacology|February 25, 2011
Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorderChing-Hua Lin, Hsien-Yuan Lane, Cheng-Chung Chen, et al.Journal of Clinical Psychopharmacology|February 25, 2011
Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medicationShawn M McClintock, Mustafa M Husain, Stephen R Wisniewski, et al.Journal of Clinical Psychopharmacology|February 25, 2011
A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorderJean-Pierre Lindenmayer, Leslie Citrome, Anzalee Khan, et al.Journal of Clinical Psychopharmacology|December 31, 2010
A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotypeHenry R Kranzler, Stephen Armeli, Howard Tennen, et al.Journal of Clinical Psychopharmacology|December 31, 2010
The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology studyElla J Daly, Madhukar H Trivedi, Maurizio Fava, et al.Journal of Clinical Psychopharmacology|December 31, 2010
Major depressive disorder: gender differences in symptoms, life quality, and sexual functionChien-Han LaiPageof 332